Market Cap 85.48M
Revenue (ttm) 440,000.00
Net Income (ttm) -35.13M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -7,984.09%
Debt to Equity Ratio 0.00
Volume 25,600
Avg Vol 70,516
Day's Range N/A - N/A
Shares Out 10.67M
Stochastic %K 9%
Beta 0.86
Analysts Strong Sell
Price Target $33.33

Latest News on AVTX

Avalo Therapeutics to Present at Upcoming Investor Conferences

Nov 11, 2024, 7:00 AM EST - 5 months ago

Avalo Therapeutics to Present at Upcoming Investor Conferences


Avalo Therapeutics Announces 1-for-240 Reverse Stock Split

Dec 27, 2023, 7:00 AM EST - 1 year ago

Avalo Therapeutics Announces 1-for-240 Reverse Stock Split


Avalo Completes Divestiture of AVTX-800 Series

Oct 31, 2023, 7:00 AM EDT - 1 year ago

Avalo Completes Divestiture of AVTX-800 Series


Top trending biotech stocks: ANVS, MTNB, AVTX, TPST

Oct 12, 2023, 11:26 AM EDT - 1 year ago

Top trending biotech stocks: ANVS, MTNB, AVTX, TPST

ANVS MTNB TPST


Avalo Enters into Agreement to Divest AVTX-800 Series

Sep 12, 2023, 7:00 AM EDT - 1 year ago

Avalo Enters into Agreement to Divest AVTX-800 Series


Avalo to Participate in SVB Securities Therapeutics Forum

Jul 6, 2023, 4:01 PM EDT - 1 year ago

Avalo to Participate in SVB Securities Therapeutics Forum


Avalo to Present at the Jefferies Healthcare Conference

Jun 1, 2023, 7:00 AM EDT - 1 year ago

Avalo to Present at the Jefferies Healthcare Conference


Avalo to Present at ATS 2023 Respiratory Innovation Summit

May 15, 2023, 7:00 AM EDT - 2 years ago

Avalo to Present at ATS 2023 Respiratory Innovation Summit


Avalo Therapeutics Announces Board Changes

Aug 11, 2022, 4:01 PM EDT - 2 years ago

Avalo Therapeutics Announces Board Changes


Avalo to Present at the 2022 Jefferies Healthcare Conference

Jun 2, 2022, 7:30 AM EDT - 3 years ago

Avalo to Present at the 2022 Jefferies Healthcare Conference